Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Company Funding for AMED-Backed Clinical Research Also Subject to Legal Regulation: Govt
June 8, 2016
- Use of MID-NET in PMS Could Promote Comparisons of One’s Own Products with Other Treatments: FPMAJ Official
June 7, 2016
- MHLW to Place 2-Year Grace Period on Mandatory Barcode Labeling by March 2021 for Companies with “Special Circumstances”
June 6, 2016
- 141 Trials of Nucleic Acid Drugs Underway Worldwide, but 70% Being Conducted by US Companies: JPO Survey
June 6, 2016
- Cabinet OKs New Growth Strategy, Basic Economic and Fiscal Policy
June 3, 2016
- “Minor Discrepancies” between Marketing Approval and Actual Manufacturing Processes Found for about 70% of Products: MHLW
June 3, 2016
- Clinical Research Bill Didn’t Clear Diet, Now under Continued Review
June 2, 2016
- Tax Hike Delay Kills Feared Price Cuts in 2017, but Concerns Linger over Expensive Drug Debate
June 2, 2016
- MHLW Proposes Discontinuing Supply of Human Thrombin Products
June 2, 2016
- MHLW Expects Stable Supply of Kaketsuken’s Blood Products Despite Earthquake Damage: Official
June 2, 2016
- Bisphosphonate Labels to Add Osteonecrosis of External Auditory Canal in ADR List
June 1, 2016
- Boehringer’s Reversal Agent for Pradaxa Becomes 1st Drug Subject to Japan’s Compassionate Use Scheme
June 1, 2016
- MHLW Initiates Discussions on Palliative Care for CV Diseases
June 1, 2016
- MHLW Drug Review Panel Shelves ASKA’s Hepatic Encephalopathy Drug
May 31, 2016
- Lawmakers Eye Genomic Medicine Bill to Fuel Diagnostics Development
May 31, 2016
- AMED to Support Drug Discovery Research Using Existing Drugs as “Tool Compounds”
May 31, 2016
- G7 Leaders Vow to Consider New Incentives to Spur AMR R&D
May 30, 2016
- MHLW Panel OKs Sanofi’s PCSK9 Inhibitor on Equal Footing with Repatha
May 30, 2016
- AZ’s Ticagrelor, Boehringer’s Triple Combo Fail to Clear MHLW Advisory Panel
May 30, 2016
- AMED to Allocate 820 Million Yen for Measures against Antimicrobial Resistance
May 27, 2016
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…